Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

SurvodutideUnderstand the science

How SYNCHRONIZE-1 counted average weight change and response rates

1 numbered sourceSource years 2026

Peptides are short amino-acid chains joined by peptide bonds. Some are designed to act at several receptors. Survodutide is an investigational peptide that activates GLP-1 and glucagon receptors. SYNCHRONIZE-1 tested it in adults with obesity or overweight and a related complication who did not have diabetes. The researchers wanted to know both how much weight changed on average and how often people reached a specified reduction. [1]

The study randomized 725 participants to two active treatment groups or placebo. All groups received lifestyle counseling. The 76-week comparison used an analysis intended to reflect treatment assignment, including the impact of some events that occurred after participants enrolled, such as stopping the study intervention. That design measures the comparison for the groups as assigned under the trial’s rules. It differs from a calculation that takes only people who followed the full treatment plan into account. [1]

Average estimated weight changes were −12.2% and −13.0% in the two survodutide groups, compared with −5.4% with placebo. About 72% of participants in either active group reached a weight reduction of at least 5%, compared with 46% in the placebo group. The two ways of presenting the outcome are related. The average describes the size of the group’s overall change, while the threshold describes how common it was to reach a particular milestone. [1]

Adverse events also differed across the groups. Gastrointestinal symptoms occurred in about 81% and 90% of participants in the active groups, compared with 48% in the placebo group. The authors said the symptoms were typically mild to moderate. Counting participants with a symptom does not show how many times they had it or how long it lasted. Those details would be necessary to answer a separate question about an individual’s course. [1]

This trial compared survodutide with placebo in a defined population and over a specified period. A head-to-head trial with another weight-management medicine would address a different question, and an event-driven cardiovascular trial would count different outcomes. The evidence reported here concerns weight change, response rates and the experiences recorded during the phase 3 obesity trial. The investigators described survodutide as investigational, and trial results alone do not establish an approved indication. [1]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Survodutide

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.